• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Results from the first comparative Portico transcatheter aortic valve trial

byMichael PratteandArnav Agarwal, MD
July 7, 2020
in Cardiology, Chronic Disease, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The Portico aortic valve had non-inferior rates of all-cause mortality and disabling stroke at 1 year after randomization compared to commercially available valves.

2. The Portico aortic valve had a higher rate of all-cause mortality and serious adverse events than commercially available valves 30 days after randomization.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In patients with aortic stenosis for whom open heart surgery has unfavorable risks, transcatheter valve replacement is considered the standard of care. Although three such valve systems are currently commercially approved by the US Food and Drug Administration, no self-expanding, flexible valve system that preserves coronary access for future treatment exists. This study (PORTICO IDE) was the first randomized controlled trial to compare the safety and efficacy of the novel self-expanding intra-annular Portico aortic valve system with that of three commercially available valves (the SAPIEN 3, Evolut R and Evolut PRO systems) among high and extreme risk patients with aortic stenosis. The Portico valve showed non-inferiority to commercial valves in the study’s primary efficacy endpoint, 1-year all-cause mortality or stroke, but was associated with higher rates of mortality and vascular, thrombotic, hemorrhagic or end-organ damage-related complications at 30 days, the trial’s primary safety endpoint. A major limitation of this study was that, due to its length, several improvements of the commercial valve systems have been released, affecting the applicability of the results. Other limitations include combining both balloon-expandable and supra-annular valve systems, each with a unique safety profile, within the control group, as well as limited experience with the Portico valve potentially causing increased safety events in some centers. To summarize, the Portico valve proved non-inferior  for 1-year all-cause mortality, but was associated with higher all-cause mortality and a worse safety profile at 30 days follow-up compared to conventional commercial valve systems in the as-treated population. These findings suggest that, given its comparable efficacy but poorer safety profile, use of the first-generation Portico valve system is generally not favorable until improvements are made.

Click to read the study in The Lancet

Relevant Reading: Transcatheter Aortic-Valve Replacement With a Self-Expanding Valve in Low-Risk Patients

In-Depth [randomized controlled trial]: This multicenter, randomized, controlled, non-inferiority study was conducted to compare the safety and efficacy of the novel, first generation self-expanding intra-annular Portico transcatheter aortic valve system with commercially available valve systems. Adults with high and extreme open heart surgical risk (chance of mortality post-operation > 15% & 50% at 30 days, respectively) with severe aortic stenosis (aortic valve area <1.0m2 and mean transvalvular pressure gradient > 40mmHg or jet velocity > 4.0m/s or doppler velocity index < 0.25) were recruited, and randomly assigned to either the Portico (n=381) or commercial valve group (n=727). Of the total population, 521 (69.5%) had an average frailty index > 2, 541 (72.1%) an NYHA class of III or IV, and 133 (17.7%) were extreme surgical risk. There were two primary endpoints, the safety endpoint being a non-hierarchical composite of all-cause mortality at 30 days after randomization, and the efficacy endpoint being a non-hierarchical composite of all-cause mortality and disabling stroke at 1 year after randomization. The Portico valve showed non-inferiority to commercial valves with its primary efficacy endpoint (14.8% vs. 13.4%, respectively; absolute difference 1.5%, 95% confidence intervals [CI] -3.6 to 6.5; upper confidence bound [UCB] 5.7%; p(non-inferiority) = 0.0058),  as well as non-inferior rates of safety events at 30 days (13.8% vs. 9.6%, respectively; absolute difference 4.2%; 95% CI -0.4 to 8.8; UCB 8.1%; p(non-inferiority) = 0.034). Of note, post-hoc superiority tests showed that the Portico valve was inferior compared to valve systems for the primary safety endpoint (absolute difference 5.0%, 95% UCB 8.9%; p=0.037). When comparing valve types individually, mortality at 2 years was higher for the Portico valve compared with the SAPIEN 3 valve, but similar between the Portico and Evolut R/ Evolut PRO valves.

RELATED REPORTS

#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery

Cerebral embolic protection during transcatheter aortic-valve replacement does not reduce the incidence of stroke

Transfemoral transcatheter aortic valve replacement vs surgical valve replacement outcomes at 5 years

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aortic stenosisEvolutEvolut PROPorticoTAVItavr
Previous Post

Cortical proteins associated with cognitive resilience in community-dwelling older persons

Next Post

Steroid bursts associated with an increased risk for severe adverse events

RelatedReports

#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery
StudyGraphics

#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery

December 20, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Cerebral embolic protection during transcatheter aortic-valve replacement does not reduce the incidence of stroke

October 10, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Cardiology

Transfemoral transcatheter aortic valve replacement vs surgical valve replacement outcomes at 5 years

August 31, 2022
Rivaroxaban after TAVR linked with increased risk of adverse events compared to antiplatelet therapy
Cardiology

Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-Year clinical outcomes

August 3, 2022
Next Post
Gender conformity influences use of laxatives and muscle-building products

Steroid bursts associated with an increased risk for severe adverse events

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

The majority of children infected with COVID-19 in Europe develop mild disease

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options